Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II

被引:16
作者
Durieux, Sophie [1 ]
Chanu, Angeline [1 ]
Bochu, Christophe [2 ]
Audinot, Valerie [3 ]
Coumailleau, Sophie [3 ]
Boutin, Jean A. [3 ]
Delagrange, Philippe [4 ]
Caignard, Daniel H. [4 ]
Bennejean, Caroline [4 ]
Renard, Pierre [4 ]
Lesieur, Daniel [1 ]
Berthelot, Pascal [1 ]
Yous, Said [1 ]
机构
[1] Univ Lille Nord France, Chim Therapeut Lab, EA 1043, Fac Sci Pharmaceut & Biol, F-59006 Lille, France
[2] Univ Lille Nord France, Lab Applicat Resonance Magnet Nucl, Fac Sci Pharmaceut & Biol, F-59006 Lille, France
[3] Inst Rech Servier, Div Pharmacol Mol & Cellulaire, F-78290 Croissy Sur Seine, France
[4] Inst Rech Servier, Dept Sci Expt, F-92150 Suresnes, France
关键词
Melatonin; Selective antagonists; MT2; receptors; Tetralins; RECEPTOR LIGANDS; CIRCADIAN-RHYTHMS; PHASE ADVANCES; HIGH-AFFINITY; ANTAGONISTS; RESPONSES; CLOCK;
D O I
10.1016/j.bmc.2009.03.023
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Following our studies of the melatoninergic receptors, we have developed new tetrahydronaphthalenic derivatives of melatonin that have been tested as selective melatonin receptors ligands. Regarding the role of the phenyl substituent to obtain selective ligands, modulation of selectivity and activity have been achieved by modi. cations of the acyl group and substitutions on the phenyl ring. Ten of the seventeen evaluated derivatives have MT2 receptor affinity similar to that of melatonin. Moreover, we have achieved remarkable MT2 selectivity over MT1 (selectivity > 100) and have been able to further extend the RSA of the tetrahydrophthalenic series. However, the compounds presented here display partial agonist or antagonist behavior instead of full agonist. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2963 / 2974
页数:12
相关论文
共 25 条
  • [1] New selective ligands of human cloned melatonin MT1 and MT2 receptors
    Audinot, V
    Mailliet, F
    Lahaye-Brasseur, C
    Bonnaud, A
    Le Gall, A
    Amossé, C
    Dromaint, S
    Rodriguez, M
    Nagel, N
    Galizzi, JP
    Malpaux, B
    Guillaumet, G
    Lesieur, D
    Lefoulon, F
    Renard, P
    Delagrange, P
    Boutin, JA
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2003, 367 (06) : 553 - 561
  • [2] Design and synthesis of N-(3,3-diphenylpropenyl) alkanamides as a novel class of high-affinity MT2 selective melatonin receptor ligands
    Bedini, Annalida
    Spadoni, Gilberto
    Gatti, Giuseppe
    Lucarini, Simone
    Tarzia, Giorgio
    Rivara, Silvia
    Lorenzi, Simone
    Lodola, Alessio
    Mor, Marco
    Lucini, Valeria
    Pannacci, Marilou
    Scaglione, Francesco
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (25) : 7393 - 7403
  • [3] Synthesis of naphthalenic melatonin receptor ligands
    Chu, GH
    Li, PK
    [J]. SYNTHETIC COMMUNICATIONS, 2001, 31 (04) : 621 - 629
  • [4] Melatonin mediates two distinct responses in vascular smooth muscle
    Doolen, S
    Krause, DN
    Dubocovich, ML
    Duckles, SP
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 345 (01) : 67 - 69
  • [5] Effect of MT1 melatonin receptor deletion on melatonin-mediated phase shift of circadian rhythms in the C57BL/6 mouse
    Dubocovich, ML
    Hudson, RL
    Sumaya, IC
    Masana, MI
    Manna, E
    [J]. JOURNAL OF PINEAL RESEARCH, 2005, 39 (02) : 113 - 120
  • [6] Melatonin receptor antagonists that differentiate between the human Mel(1a), and Mel(1b) recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML(1) presynaptic heteroreceptor
    Dubocovich, ML
    Masana, MI
    Iacob, S
    Sauri, DM
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 355 (03) : 365 - 375
  • [7] Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms
    Dubocovich, ML
    Yun, K
    Al-Ghoul, WM
    Benloucif, S
    Masana, MI
    [J]. FASEB JOURNAL, 1998, 12 (12) : 1211 - 1220
  • [8] DUBOCOVICH ML, 2000, IUPHAR MEDIA
  • [9] DURIEUXPOISSONN.S, 2008, BIOORGAN MED CHEM, V16, P8339
  • [10] Activation of MT2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock
    Hunt, AE
    Al-Ghoul, WM
    Gillette, MU
    Dubocovich, ML
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2001, 280 (01): : C110 - C118